In a previous study (see Ref. 7), the molecular weight distribution of inhibin activity in fractionated human follicular fluid (hFF) and human male and female plasma/serum was determined by in vitro bioassay using ovine pituitary cells in culture and various specific inhibin A and inhibin ␣-subunit-directed immunoassays. It was shown, however, that the ovine in vitro bioassay detected inhibin B poorly. These findings are extended in the present study by the determination of the molecular weight profile of in vitro bioactivity using rat pituitary cells, which detects both inhibin A and B, a specific inhibin B enzyme-linked immunosorbent assay (ELISA), an RIA detecting the ␣N region of the ␣-subunit, an ␣-subunit ELISA (Pro-␣C) directed to the inhibin forms containing the Pro sequence, and an ␣C subunit immunofluorometric assay that detects all inhibin forms. The profile in hFF of inhibin in vitro bioactivity, using rat pituitary cells in culture, significantly (P Ͻ 0.001) correlated with in vitro bioactivity using ovine pituitary cells (r ϭ 0.85), inhibin A immunoactivity (r ϭ 0.70), inhibin B immunoactivity (r ϭ 0.89), and the combination of inhibin AϩB immunoactivities (r ϭ 0.93), with peaks of activity identified at 66K, 55K, 36K and 33K, consistent with presumed known mol wt forms of inhibin. Inhibin B profiles in fractionated serum from women stimulated with gonadotropins and male plasma consisted of two forms (66K and 36K), whereas inhibin A in female serum included, in addition, the 55K form. These findings indicated that higher molecular weight forms of inhibin B are present in biological samples, and their distribution differs from that of inhibin A, suggesting a differential processing of the precursor forms in the circulation. Pro-␣C immunoactivity was identified in serum samples with prominent peaks at 36K and 29K (known Pro-␣C subunit forms) and not with any high mol wt dimeric forms of inhibin. If this observation applies to a wider range of serum samples, the Pro-␣C ELISA may provide an appropriate and specific assay for the measurement of free ␣-subunit. To compare immunoactivity levels between assays, the inhibins A, B, and Pro-␣C standards were calibrated in terms of their ␣C subunit content, as determined by an ␣C subunit immunoassay, with the inhibin B standard containing 60% of the ␣C subunit content compared with either the inhibin A or Pro-␣C standard. After adjustments of the various standards for this difference in ␣C subunit content, a comparison was undertaken of the combined levels of inhibins A, B, and Pro-␣C immunoactivity across the hFF and serum chromatograms and compared with levels determined by the ␣-subunit-directed immunoassays. A high correlation (r ϭ 0.59 -0.96) was observed, indicating that the ␣-subunit immunoactivity in serum consists largely of a composite of presumed known molecular weight forms of inhibins A, B, and Pro-␣C. It is concluded that: 1) inhibin in vitro bioactivity in hFF is largely attributed to the presence of 33-36K and 50 -66K forms of inhibins A and B; and 2) inhibin ␣-subunit immunoactivity in hFF and serum is a composite of presumed known forms of inhibin A, inhibin B, and the ␣-subunit. (J Clin Endocrinol Metab 82: 889 -896, 1997) 
I
NHIBIN is a dimeric glycoprotein produced by the gonads with a recognized role in inhibiting FSH secretion (for reviews, see Refs. [1] [2] [3] [4] . Inhibin consists of two partially homologous subunits, ␣ and either ␤A (inhibin A) or ␤B (inhibin B). A large number of molecular weight forms of inhibin have been identified (5) (6) (7) (8) (9) (10) , which are attributed to processing of its precursor subunits at recognized basic amino acid cleavage sites after dimerization or to differential glycosylation with the presence of one or two carbohydrate chains located in the carboxy region of the ␣-subunit. In addition, various processed forms of the biologically inactive ␣-subunit have now been identified (11) (12) (13) (14) . The biological activity of many of the forms of inhibin seems to reside in the mature 30K form. However, an NH 2 -terminal region of the ␣-subunit (termed ␣N subunit) seems to exhibit a different activity to inhibin (15) . Furthermore, it has been shown (8) that a dimer of the full-length unprocessed ␣-and ␤-subunits, where the processing sites have been mutated to prevent cleavage, was bioinactive in suppressing FSH in vitro.
It has become apparent that inhibin and its ␣-subunit may exist in biological samples as a range of molecular weight forms. In a previous companion paper (7), inhibin from human follicular fluid (hFF) and serum/plasma from men and women was fractionated according to molecular size and the profiles of inhibin in vitro bioactivity, and immunoactive inhibin A and ␣-subunit containing inhibin forms identified. Inhibin was found to be present in these fluids in all the recognized forms with some evidence of additional cleavage products. Several issues arose out of this study that required further clarification. Firstly, this study showed that the in vitro bioassay employed using ovine pituitary cells, though highly sensitive to inhibin A, was relatively insensitive to inhibin B, and thus, the in vitro bioassay pattern was probably reflecting inhibin A only. Secondly, the pattern of inhibin B was unknown. These aspects are examined in the present study, with the addition of an in vitro bioassay (using rat pituitary cells), which detects both inhibins A and B, an RIA that detects the ␣N region of the ␣-subunit and the recent availability of a specific inhibin B enzyme-linked immunosorbent assay (ELISA). An ␣-subunit ELISA (Pro-␣C) directed to the inhibin ␣C subunit containing the Pro-sequence and an ␣-subunit immunofluorometric assay (IFMA) that detects all inhibin forms containing the ␣-subunit were also examined.
Materials and Methods

Molecular weight identification of inhibin and inhibinrelated proteins
Molecular weight designations employed in this study are similar to those used previously (7) . For a further elaboration of molecular weight forms of human inhibin, see Mason et al. (8) . Known forms of the inhibin ␣-subunit are Pro-␣N-␣C (50 -60K), ␣N-␣C (45K), and Pro-␣C (26 -30K). Known forms of dimeric inhibin A and B are (Pro)-␣N-␣C/pro␤-␤ (90 -105K), ␣C/pro␤-␤ (75K), (Pro)-␣N-␣C/␤ (55-66K), and ␣C/␤ (30 -34K). Two glycosylated forms of the ␣C subunit have been identified that result in additional molecular weight forms differing by 3K. These glycosylated forms are more evident in the 20 -40K region of the chromatograms. In this and the previous study (7) , mol wt for some inhibin forms were different from that reported (8) , e.g. inhibin ␣/␤A (30 -34K) is shown in this study with mol wt of 33-36K and ␣C/pro␤-␤ (75K) migrates at 66K. These differences are attributed to methodological differences, including choice of protein standards used in the assessment of molecular weights in the SDS-PAGE.
Preparations
The first international standard for inhibin A, (human recombinant, 91/624, 30 -34K) was obtained from the NIBSC, Potters Bar, UK. To compare data with the previous study, in vitro bioactivity and immunoactivity were expressed in terms of its nominal vial content (5 g). To relate data to the first international inhibin standard, an adjustment factor of 30,000 IU/g is used (16) . Recombinant human inhibin B (30K) was a gift from Dr. J. Mather and used in the previous study (7) . The Groome inhibin B standard was purified from hFF on an immunoaffinity column consisting of immobilized ␣C subunit directed monoclonal antibody (R1), eluted in guanidinium hydrochloride, diluted in water containing 1% BSA and lyophilized (17) . Pro-␣C preparation used as standard was a purified preparation consisting of two mol wt forms (24K and 27K) (18) . Some aspects of the purity of these preparations are included in Table 1 .
Biological samples and fractionation procedure
The samples investigated originated from an earlier study (7) . hFF, serum from women undergoing gonadotropin treatment as part of an in vitro fertilization program (IVF serum), plasma from women after menopause, and male plasma were fractionated by a combined procedure consisting of an inhibin ␣C subunit immunoaffinity purification step, reversed phase high performance liquid chromatography (HPLC) and preparative PAGE (Prep-PAGE). The gel slices were electroeluted and the inhibin removed from the SDS elution buffer by methanol precipitation. The same sample aliquots used in the previous study (7) were used in the present study, to allow direct comparisons.
In vitro bioassay using rat pituitary cells in culture
The method of Scott et al. (19) was employed, except FSH release, rather than FSH content, was used as assay endpoint. Inhibin A (91/624) was used as standard.
In vitro bioassay using ovine pituitary cells in culture
The method of Tsonis et al. (20) was employed. Data presented in this paper using this method was presented previously (7) and is included for comparison purposes. Inhibin A (91/624) was used as standard.
Inhibin A (␣␤A) ELISA
The method of Groome and O'Brien (21) was employed. Data presented in this paper using this method was presented previously (7) and is included for comparison purposes. Inhibin A (91/624) was used as standard.
Inhibin B (␣␤B) ELISA
The method of Groome et al. (17) was employed without modifications. The monoclonal antibody (C5) to a carboxy terminal peptide of the inhibin ␤B subunit was employed as capture antibody with the Fabalkaline phosphatase conjugate of monoclonal antibody (R1) to the ␣-subunit peptide (1-32) of human inhibin ␣C subunit as label. The alkaline phosphatase activity was amplified using the Gibco kit (Life Technologies, Gaithersburg, MD). Samples were initially boiled in 2% SDS and treated with hydrogen peroxide. The Groome inhibin B preparation was used as standard. The sensitivity of the assay was 15 pg/mL. The specificity of the assay is presented in Table 1 .
Pro-␣C subunit ELISA
The ELISA of Groome et al. (18) was employed without modifications. The monoclonal antibody (INPRO13) directed against the entire Pro region of human ␣-subunit was used as capture antibody with the Fab-alkaline phosphatase conjugate of monoclonal antibody (R1) to the ␣C subunit peptide of human inhibin as label. The alkaline phosphatase activity was amplified using the Gibco kit. The Groome Pro-␣C preparation was used as standard. The sensitivity of the assay was 6 pg/mL. The specificity of the assay is presented in Table 1 .
␣N subunit RIA
The RIA consisted of an antiserum (no. 52) raised in sheep to a fusion protein fragment of the bovine ␣N-subunit precursor region (amino (15) . The sensitivity of the assay was 16 pg/tube. Recombinant human inhibin A showed no crossreaction with the addition of 2500 pg/well (Ͻ0.6%) in the assay. Insufficient sample was available to apply this assay across the serum Prep-PAGE chromatograms.
␣C subunit IFMA
A two-site IFMA was developed with the aim of detecting all ␣C subunit-containing inhibin forms. The capture antibody used was a caprylic acid IgG cut of a sheep polyclonal antibody (no. 128) raised initially against human inhibin ␣C subunit fusion protein (22) and subsequently boosted with recombinant inhibin A. The antibody used as label was a sheep polyclonal antibody (no. 41) raised against human inhibin ␣C subunit fusion protein (22) , immunopurified against bovine inhibin ␣C subunit fusion protein, and biotinylated (4 h at room temperature) using the biotin-isothiocyanate procedure (Wallac, Turku, Finland) in 50 mmol/L Na 2 CO 3 buffer, pH 9.8, at a 60-to 90-fold molar excess of biotin reagent. The sheep antisera and fusion protein were gifts from Biotech Australia P/L, Sydney, Australia. Ninety-six well microtitre plates (Maxisorb, Nunc, Roskilde, Denmark) were coated with 2 g/well capture antibody in glycine buffer, pH 4.4, and blocked for 1 day at room temperature with 50 mmol/L Tris/HCl, 1% BSA, pH 7.5. Assay buffer used was 50 mmol/L Tris/HCl, 0.154 mol/L NaCl, 0.1% NaN 3 , 0.5% BSA, pH 7.4 (TSA.BSA) containing 0.1% ovine IgG. Sample and standard (200 L) were incubated in the antibody-coated microtitre plate for 2 h at room temperature with shaking. The plate was then washed and biotinylated antibody (200 ng/well) was added and incubated a further 2 h at room temperature. After washing, Eu-streptavidin (50ng/well, Wallac) was added, incubated 30 min, washed 6 times, and enhancement solution (23) was added. The plates were read on a Wallac 1234 Fluorometer. The dose response curves were log-log transformed and, where appropriate, potencies determined using parallel-line bioassay statistics. The sensitivity of the assay was 30 pg/mL (or 0.9 IU/mL) in terms of the inhibin A (91/624) standard (16) with a working range of 30 -50,000 pg/mL. Inhibin A (91/624) was used as standard.
Reductive alkylation
Two to three samples of each preparation (Table 1) were diluted in an equal volume of 0.2 mol/L Tris/HCl, 6 mol/L guanidinium hydrochloride, 2 mol/L EDTA, pH 7.5. Dithiothreitol (2:1 wt/wt protein) was added and incubated at 37 C for 3 h. Iodoacetic acid (2:1 wt/wt dithiothreitol) in 1 mol/L Tris/HCl, pH 7.9, was added and incubated for 15 min in the dark. The samples were gel filtered in TSA.BSA buffer before ␣C-subunit determination by IFMA.
Previous studies (24) had shown that the oxidized form of inhibin A, which is present to a variable extent in inhibin preparations, exhibited a higher affinity for an inhibin monoclonal antibody in an ␣␤-ELISA, resulting in spurious immunoassay results. To ensure that differences in measured ␣C content between preparations were not caused by this effect, the reduced and alkylated samples (100 L) also were oxidized with H 2 O 2 (50 L, 5%) and incubated at room temperature for 30 min. TSA.BSA buffer (200 L) was added and samples assayed in the ␣C subunit IFMA.
Statistical analyses
Prep-PAGE fractions were assayed at one dose level in all immunoassays. Prep-PAGE samples assayed in the inhibin in vitro bioassay and samples used in the specificity studies were assessed at multiple doses and assayed, where appropriate, by parallel-line statistics.
Results
Specificities of assays
The specificity of the various immunoassays (Table 1) was investigated. In the inhibin B ELISA, no significant crossreaction (Ͻ0.1%) was observed with inhibin A or Pro-␣C, although the two inhibin B preparations showed different levels of activity. The inhibin A ELISA also showed high specificity, as shown previously (7); however, the two inhibin A preparations also showed different levels of activity. The Groome inhibin B preparation contained significant amounts of inhibin A and some Pro-␣C.
The differences in activity between the two inhibin A and the two inhibin B preparations suggested that the designated mass estimates of some of these preparations were not correct. If this is the case, then the use of some of these preparations as standards in the immunoassays will lead to an incorrect assessment of the levels of the various inhibins in the samples. Because inhibins A, B, and Pro-␣C all contain the ␣C subunit, an ␣C subunit IFMA was used that quantitates the levels of the inhibin ␣C subunit. Inhibins A, B, and Pro-␣C were reduced and alkylated to release the ␣-subunit from the dimer, and the ␣-subunit content was determined in the ␣C IFMA using inhibin A (91/624) as reference preparation. The immunoactivity of the various preparations was increased 2-to 4-fold after reductive alkylation, although similar relative values, compared with the untreated samples (Table 1) , were obtained. When standardized against inhibin A (91/624) standard, large differences in ␣-subunit content were noted between preparations, ranging from 16 -2914% of stated values. The addition of the oxidative step did not change the immunoactivities of the various preparations (Table 1). Fig. 1) A comparison of the inhibin in vitro bioactivity, as determined using ovine pituitary cells (specific for inhibin A) and rat pituitary cells (specific for inhibins A and B) across the hFF Prep-PAGE chromatogram, showed highly comparable profiles (r ϭ 0.85, P Ͻ 0.001) between activities. Similar peaks of bioactivity were identified at 66K, 55K, 36K, and 33K, with 5-times higher levels of bioactivity, using the rat in vitro bioassay (Fig. 1) .
Fractionation of hFF (
Inhibin B immunoactivity showed a pattern similar to both inhibin in vitro bioactivity and inhibin A immunoactivity. The levels of inhibin B and inhibin A, alone and in combination, correlated closely with the rat in vitro bioassay (r ϭ 0.70 -0.93) ( Table 2 ). The Pro-␣C immunoactive profile consisted of peaks at ϳ55K, 33-36K, and 29K with no evidence of higher mol wt forms. An immunoactive ␣N subunit peak consistent with either (Pro)-␣N-␣C or (Pro)-␣N-␣C/␤ was identified as a relatively broad peak at 55K. ␣C subunit immunoactivity, as determined by ␣C IFMA, showed a similar pattern of immunoactivity to that seen with the other ␣-subunit immunoassays (7) with major peaks at 66K, 55K, 33-36K, and 29K (Fig. 1) . (Figs. 2 and 3) Inhibin B immunoactivity was determined with peaks at 60 -66K and 36K only, with little or no immunoactivity at 55K (as seen with inhibin A). Pro-␣C immunoactivity was detectable at 36K and 29K with low, but detectable, levels elsewhere.
Fractionation of IVF serum and postmenopausal plasma
Inhibins A and B were undetectable in postmenopausal plasma, whereas Pro-␣C immunoactivity and ␣-subunit immunoactivity, using the ␣C IFMA, were detectable as a broad range between 30K and 60K. In addition, a peak at ϳ20K, consistent with the presence of the ␣C subunit, was identified with the ␣C IFMA.
Fractionation of male plasma (Fig. 4) Male plasma showed two peaks of inhibin B immunoactivity at 66K and 36K, similar to that seen for IVF serum. It was shown previously (7) that no inhibin A activity was detected across this chromatogram. Pro-␣C immunoactivity showed a similar pattern to that seen with hFF and IVF serum, with peaks at 55K, 36K, and 29K. In addition, minor immunoactive peaks determined by the ␣C IFMA were observed at ϳ100K and ϳ20K.
Adjustment of inhibins A, B, and Pro-␣C values across the chromatograms according to the ␣C subunit content of the respective standards in the various assays
The relative levels of the inhibins A, B, and ␣-subunit profiles detected in the chromatograms are dependent, in part, on the designated unitage of the standards employed in the various assays. To compare values obtained between FIG. 1. Molecular weight distribution of inhibin in vitro bioactivities, employing either ovine or rat pituitary cells in culture, and various immunoactivities in hFF, fractionated through a combined immunoaffinity preparative SDS-PAGE procedure. The 66K peak corresponds to ␣C/pro␤-␤, the 55K peak to (Pro)-␣N-␣C/␤ and Pro-␣N-␣C, 33K and 36K peaks to ␣/␤, and 29K and 33K peaks to Pro-␣C. Please note the differences in levels of immunoactivities for the two profiles in the bottom panel. Values above assay sensitivity in both assays are included in the analysis.
a Results have been corrected for ␣C subunit content in the inhibin B standard (see Results section for details).
FIG. 2. Molecular weight distribution of inhibin immunoactivities in
serum from women stimulated with gonadotropins (IVF serum), fractionated through a combined immunoaffinity preparative SDS-PAGE procedure. The horizontal line refers to the level of sensitivity of the assay. The 100K peak corresponds to Pro-␣N-␣C/pro␤-␤. See the legend to Fig. 1 for further details. assays, the inhibins A, B, and Pro-␣C standards were recalibrated in terms of their ␣C subunit content using the ␣C subunit IFMA (Table 1 ). The Pro-␣C standard showed levels of ␣C subunit similar to the inhibin A (91/624) standard. In the case of the Groome inhibin B standard, because of its large content of ␣-subunit-like immunoactivity, its inhibin B levels were initially measured in the inhibin B ELISA in terms of the highly purified Genentech inhibin B preparation, which in turn, was adjusted for its ␣C subunit content after assay in the ␣C subunit IFMA. These adjustments in the calibration of the various standards resulted in a change in the relative levels of the inhibin A, B, and Pro-␣C across the various chromatograms. The largest change was with inhibin B, which was 60% of its original value compared with inhibin A (100%) and Pro-␣C (109%). A comparison between the hFF profile of inhibin in vitro bioactivity using rat pituitary cells and the profile of the sum of inhibin A and inhibin B immunoactivities showed a very good correlation (r ϭ 0.93) with a slope of the regression line close to unity (Table 2, Fig.  1) . A comparison between the combined levels of inhibin A, B, and Pro-␣C immunoactivities and ␣-subunit immunoactivity determined with the various ␣-subunit immunoassays of both hFF and plasma/serum profiles also showed high correlations, although the slopes of the regression lines varied markedly between assays (Table 3 , Figs. 1-4 ).
Relative levels of inhibin A, B, and Pro-␣C in hFF and serum/plasma (Table 4)
The levels of inhibin A, B, and Pro-␣C in hFF and serum, when the standards are adjusted for their ␣C subunit content and compared with their ␣C IFMA values, are presented in Table 4 . The Pro-␣C levels in hFF and IVF serum (Table 4) represent immunoactivity identified in the 29 -36K region only, excluding the 45-55K region because the 45-55K region may be either ␣-subunit monomer (Pro-␣N-␣C) or ␣␤-subunit dimer (Pro-␣N-␣C/␤).
Discussion
The present and earlier study (7) provide a basis for characterizing the forms of inhibin in hFF and human plasma/serum.
Calibration of standards
Results from the specificity studies (Table 1) of 16% compared with the inhibin A (91/624) standard, indicating that the stated inhibin content of this preparation was overestimated. This 16% value compares favorably with the cross-reaction values previously observed (7) with the inhibin in vitro bioassay (17.2%) and two immunoassays (Medgenix ␣-␣ ELISA, 16.7% and inhibin RIA, 12.3%). These low values are in contrast to that obtained with the Genentech Ck/Ck ELISA, where a value of 82% was obtained (7) . It should be noted that the Genentech Ck/Ck ELISA measurements were undertaken at Genentech, whereas all other stated assays were undertaken in Melbourne. These findings suggest that for reasons unknown, the inhibin B preparation tested in Melbourne was of reduced activity compared with the preparation tested by Genentech. Based on the ␣C subunit content of inhibin A and inhibin B, the cross-reaction of inhibin B in the rat in vitro bioassay and the various immunoassays is increased (now ranging between 77 and 104% of that of inhibin A). Thus, inhibin B cross-reacts equally well with inhibin A in the rat in vitro bioassay and various ␣-subunit immunoassays (Monash RIA and Medgenix ␣-␣ ELISA). Nonetheless, the cross-reaction of inhibin B in the ovine in vitro bioassay, with correction for ␣C subunit content, is still low (5.6%), indicating that ovine pituitary cells, in contrast to rat pituitary cells, are relatively insensitive to inhibin B. These findings highlight the need for high quality standards, particularly in situations where comparisons between assays are intended. Thus, there is a need for an international reference preparation for inhibin B, and possibly Pro-␣C, as in the case for inhibin A (16) .
hFF
The combined profile of inhibin A and B immunoactivity in hFF correlated closely (r ϭ 0.93) with inhibin in vitro bioactivity, as determined with the rat bioassay, suggesting that the sum of the two immunoassays provides a good measure of inhibin bioactivity in this sample. However, based on the slope of the regression line (Table 2) , the combined inhibin AϩB levels were 1.58 times higher. When the standards were corrected for their ␣C subunit content, the slope of the regression line was 1.1. These data strongly suggest that the inhibin in vitro bioactivity in hFF is largely attributed to the presence of various known molecular weight forms of inhibin A and B.
The four peaks of inhibin immunoactivity and bioactivity (66K, 55K, 36K, and 33K) in the hFF chromatogram can now be broadly identified. The 66K peak most likely consists of ␣C/pro␤-␤, as assessed from its mol wt, its bioactivity, and the absence of ␣N subunit. No discernible levels of either Pro-␣N-␣C/pro␤-␤ or Pro-␣N-␣C/␤ were evident. The 55K region consists of Pro-␣N-␣C and ␣N-␣C/␤, based on the coelutions of dimer activity, ␣N subunit, and 55K Pro-␣C immunoactivity, although it is not possible to establish the relative proportions. Free ␣N would not be detected in this chromatogram, because it would not bind to the ␣C subunit immunoaffinity column used in the fractionation procedure. The 36K form is attributed to ␣␤A or ␣␤B. In the previous study (7), the 33K peak was attributed to either monoglycosylated ␣␤A or B or a cleavage product of 36K inhibin, based on the absence of 33K in serum and the observation that an inhibin A immunoassay failed to detect it. This aspect is discussed further below. The failure to see significant amounts of 95-105K forms of inhibin is attributed to the particular hFF batch examined in this study. Higher proportions of these inhibins have been identified in chromatograms in an earlier study (6) , indicating that these forms are detectable in hFF in this combined fractionation/assay system.
The Pro-␣C ELISA, though previously shown (20) to detect ␣C IFMA y ϭ 0.99x Ϫ 0.07 r ϭ 0.81
The RIA, Genentech Ck/Ck, and Medgenix ␣Ϫ␣ immunoassay data have been published previously (7). 
IVF serum, postmenopausal and male plasma
The mol wt profiles of inhibin B immunoactivity in IVF and male plasma/serum share similarities with peaks at ϳ66K and 36K, whereas the inhibin A profile in IVF serum showed an additional peak at 55K. Based on the similar inhibin A and B profiles in hFF and the different patterns of inhibins A and B in plasma, it is concluded that inhibins A and B are differentially processed in the circulation. Inhibin A, with the exception of the 33K form absent in serum, has a similar profile to that found in hFF and reflects processing of both ␣-and ␤-subunit precursor forms. Inhibin B in serum, however, shows an absence of the 55K form, which is believed to be ␣N-␣C/␤, whereas the 66K form (␣C/pro␤-␤) is retained. A similar absence of the 55K form of inhibin B was evident in male serum.
The Pro-␣C ELISA primarily detects monomeric ␣-subunit forms in serum with little evidence for the detection of higher molecular weight dimeric inhibin forms (e.g. Pro-␣N-␣C/␤, Pro-␣N-␣C/pro␤-␤). This assay previously has been shown to detect Pro-␣C containing dimeric inhibin forms, thus indicating that in serum, the levels of these high-molecular weight forms are low. If this observation is confirmed in a wider range of serum samples, then this assay seems to be unique in detecting the free Pro-(␣N)-␣C subunit in serum, because other ␣-subunit assays detect all ␣C subunit-containing proteins, including inhibin dimeric forms. Thus, the Pro-␣C and inhibin A or B assays, when applied to serum under these specified conditions, would be showing assayindependent effects. However, the Pro-␣C ELISA would be unable to detect the free ␣C subunit (minus the Pro-region). There is a suggestion of the presence of the free ␣C subunit in the male and postmenopausal plasma chromatograms, in particular, based on its mol wt (ϳ20K) and its detection by the ␣C IFMA but not by the Pro-␣C ELISA. This issue requires further examination. Previous studies (17) have shown that inhibin B, and not inhibin A, was detected in male serum, and this was confirmed in these studies.
Pro-␣C and ␣-subunit immunoactivity, but not inhibin A or B immunoactivity, was detected across the Prep-PAGE profile of postmenopausal plasma. Some of the forms (21K, 29K, 36K, and possibly 55K) are consistent with known, or presumed known, ␣-subunit forms. The identification of the ϳ21K peak with the ␣C IFMA suggests that it is the free ␣C subunit. The origin of this immunoactivity in postmenopausal plasma, with the absence of inhibin A and B, has yet to be established.
The availability of the ␣C IFMA and other ␣-subunit immunoassays provides an opportunity to compare quantitatively in hFF and plasma the profiles of ␣C subunit immunoactivity with the combined or additive levels of inhibin A, B, and Pro-␣C immunoactivity determined across the same chromatograms. The inhibin B levels were adjusted for the ␣C content in the inhibin B standard. In hFF, with several of the ␣-subunit immunoassays (Table 3) , a high correlation (hFF r ϭ 0.90 -0.96) was obtained with the combined inhibin A, B, and Pro-␣C values, with slope values ranging between 0.1 and 3. In serum, the correlations were lower (0.64 -0.91), reflecting differences between immunoactivity profiles (for example, in the 20K region, where ␣C subunit immunoactivity was detectable with the ␣C IFMA but not with the Pro-␣C ELISA). Not withstanding these differences, the close correlation among levels determined with several of the immunoassays (including the ␣C IFMA) and the combined inhibin A, B, and Pro-␣C values suggests that the profile of hFF and serum inhibin can be described appropriately in terms of these inhibin A, B and ␣-subunit immunoactivities, although the precise structures of many of these forms are unknown. These findings provide a useful platform from which to explore situations where inhibin may be modified in health and disease, for example, in the monitoring of various types of ovarian cancer (25, 26) .
In Table 4 , the adjusted concentrations of inhibin A, B, and Pro-␣C in the hFF and serum/plasma pools are presented. It is evident that in these samples, the levels of Pro-␣C are elevated (1.3-to 20-fold), compared with inhibin A and B and substantiate findings from several studies (17, 18) .
In summary, inhibin in vitro bioactivity is largely attributed to the presence of different molecular weight forms of inhibin A and inhibin B in hFF and serum. Inhibin A, B, and Pro-␣C immunoactivity correlate closely with levels of inhibin determined by ␣-subunit-directed immunoassays, suggesting that these activities, with some caveats, will provide a reasonable description of the inhibin forms present in biological samples. These findings provide a basis for understanding the patterns of circulating inhibins and related proteins observed in various physiological conditions.
